Leuven researchers turn a staphylococcus trick against the bacterium itself and outperform vancomycin in mice
The FibriLysin molecule first breaks down the protective shell of an abscess and then kills the bacteria, although it has not yet been tested in humans.
Researchers at KU Leuven's Laboratory of Gene Technology, working with the AO Research Institute Davos in Switzerland, have developed a new approach against Staphylococcus aureus, a bacterium often involved in hospital infections. The study, with Professor Rob Lavigne as senior author, was published in Nature Microbiology. KU Leuven announced the result this week and De Morgen reported on it on Friday. According to the newspaper, the bacterium causes problems in around 5 percent of operations. It evades antibiotics and the immune system by forming abscesses: clusters of bacteria wrapped in a protective coat made of the body's own proteins. That makes infections around implants and in broken bones particularly hard to treat.
The technique, called FibriLysin, combines two functions in a single molecule. A first part locally breaks down the protein coat and exposes the bacteria. According to the summary in Nature Microbiology, it does so using an enzyme the bacterium itself relies on to escape. A second part, an endolysin, then breaks down the bacterial cell wall. In laboratory tests and in a mouse model of an implant-related infection, the molecule outperformed the standard antibiotic vancomycin. It also worked against a broad range of patient samples, including the resistant MRSA strain.
Because FibriLysin works differently from antibiotics, it can be given alongside existing drugs, which then reinforce each other, and may also be useful against resistant bacteria, according to KU Leuven. The work is still preclinical, however. The team is looking for partners and investors to move the technology faster towards clinical use, but there is no timeline.